Parainfluenza virus type 3

Common Name(s)

Parainfluenza virus type 3

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Parainfluenza virus type 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Parainfluenza virus type 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Parainfluenza virus type 3" returned 109 free, full-text research articles on human participants. First 3 results:

A leucine residue in the C terminus of human parainfluenza virus type 3 matrix protein is essential for efficient virus-like particle and virion release.
 

Author(s): Guangyuan Zhang, Shengwei Zhang, Binbin Ding, Xiaodan Yang, Longyun Chen, Qin Yan, Yanliang Jiang, Yi Zhong, Mingzhou Chen

Journal: J. Virol.. 2014 Nov;88(22):13173-88.

 

Paramyxovirus particles, like other enveloped virus particles, are formed by budding from membranes of infected cells, and matrix (M) proteins are critical for this process. To identify the M protein important for this process, we have characterized the budding of the human parainfluenza ...

Last Updated: 21 Oct 2014

Go To URL
Terminal sialic acid linkages determine different cell infectivities of human parainfluenza virus type 1 and type 3.
 

Author(s): Keijo Fukushima, Tadanobu Takahashi, Seigo Ito, Masahiro Takaguchi, Maiko Takano, Yuuki Kurebayashi, Kenta Oishi, Akira Minami, Tatsuya Kato, Enoch Y Park, Hidekazu Nishimura, Toru Takimoto, Takashi Suzuki

Journal: Virology. 2014 Sep;464-465():424-31.

 

Human parainfluenza virus type 1 (hPIV1) and type 3 (hPIV3) initiate infection by sialic acid binding. Here, we investigated sialic acid linkage specificities for binding and infection of hPIV1 and hPIV3 by using sialic acid linkage-modified cells treated with sialidases or sialyltransferases. ...

Last Updated: 6 Sep 2014

Go To URL
Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
 

Author(s): Bo Liang, Shirin Munir, Emerito Amaro-Carambot, Sonja Surman, Natalie Mackow, Lijuan Yang, Ursula J Buchholz, Peter L Collins, Anne Schaap-Nutt

Journal: J. Virol.. 2014 Apr;88(8):4237-50.

 

A recombinant chimeric bovine/human parainfluenza type 3 virus (rB/HPIV3) vector expressing the respiratory syncytial virus (RSV) fusion F glycoprotein previously exhibited disappointing levels of RSV F immunogenicity and genetic stability in children (D. Bernstein et al., Pediatr. ...

Last Updated: 27 Mar 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Parainfluenza virus type 3" returned 1 free, full-text review articles on human participants. First 3 results:

Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials.
 

Author(s): Min-Shi Lee, Robert E Walker, Paul M Mendelman

Journal: Hum Vaccin. ;1(1):6-11.

 

Respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) are two leading causes of lower respiratory illness (LRI) in infants. Many efforts have been directed to develop vaccines against these two viruses. Licensure of new vaccines includes three phases of clinical ...

Last Updated: 13 Oct 2006

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.